GGrantIndex
← Leaderboards

Scot C Remick

Case Western Reserve University

Google Scholar ↗PubMed ↗ORCID ↗
$11,938,221
Attributed
$16,379,506
Total exposure
26
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,379,506 · 26

By mechanism

UG1$6,971,477 · 1
U01$5,203,972 · 2
D43$2,684,678 · 2
R01$922,682 · 1
M01$596,697 · 20

Top collaborators

Most similar at Case Western Reserve University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchNeoplasm /Cancer ChemotherapyHuman SubjectHuman Therapy EvaluationPharmacokineticsDrug Screening /EvaluationClinical TrialsAntineoplasticsDrug Adverse EffectCombination ChemotherapyClinical Trial Phase IPatient Oriented ResearchMalignant NeoplasmsResearch PersonnelHospitalsCooperative StudyResourcesMedicalTranslational ResearchLeadershipAids Related Neoplasm /CancerHealthcareCancer CareAward

Grant awards (73)

MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$1,076,001
UG1 · FY2025 · CA · contact PI
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$1,076,001
UG1 · FY2024 · CA · contact PI
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$1,109,279
UG1 · FY2023 · CA · contact PI
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$1,050,305
UG1 · FY2022 · CA · contact PI
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$837,517
UG1 · FY2021 · CA · contact PI
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$837,517
UG1 · FY2020 · CA · contact PI
A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study$128,919
UG1 · FY2020 · CA · contact PI
MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan$855,938
UG1 · FY2019 · CA · contact PI
Cancer and tobacco control training and research across the lifespan in Kenya$207,530
D43 · FY2015 · TW · contact PI
Cancer and tobacco control training and research across the lifespan in Kenya$207,230
D43 · FY2014 · TW · contact PI
Developing Research Capacity for AIDS Malignancy in Kenya$244,652
D43 · FY2013 · CA · contact PI
Cancer and tobacco control training and research across the lifespan in Kenya$203,108
D43 · FY2013 · TW · contact PI
Developing Research Capacity for AIDS Malignancy in Kenya$530,865
D43 · FY2012 · CA · contact PI
Cancer and tobacco control training and research across the lifespan in Kenya$216,008
D43 · FY2012 · TW · contact PI
Developing Research Capacity for AIDS Malignancy in Kenya$536,975
D43 · FY2011 · CA · contact PI
Developing Research Capacity for AIDS Malignancy in Kenya$538,310
D43 · FY2010 · CA · contact PI
CWRU/UHICC Phase I Trials of Anticancer Agents$820,294
U01 · FY2006 · CA · contact PI
COMBRETASTATIN A-4 PHOSPHATE IN ADVANCED ANAPLASTIC THYROID CARCINOMA$43,431
M01 · FY2006 · RR · contact PI
COMBRETASTATIN/DOXORUBICIN/CISPLATIN FOR PATIENTS WITH THYROID CANCER$20,892
M01 · FY2006 · RR · contact PI
EPOTHILONE B ANALOGUE BMS-247550 IN PTS WITH MALIGNANCIES & LIVER DYSFUNCTION$10,445
M01 · FY2006 · RR · contact PI
PS-341 IN PATIENTS WITH ADVANCED MALIGNANCIES AND RENAL DYSFUNCTION$8,246
M01 · FY2006 · RR · contact PI
BRYOSTATIN 1 + VINCRISTINE IN NON-HODGKIN'S LYMPHOMA POST TRANSPLANT$5,497
M01 · FY2006 · RR · contact PI
17-DIMETHYLAMINOETHYLAMINO-17DEMETHOXYGELDANAMYCIN IN ADVANCED SOLID TUMORS$4,399
M01 · FY2006 · RR · contact PI
17-ALLYLAMINO-17 DEMETHOXYGELDANAMYCIN (17-AAG) W/PACLITAXEL IN ADV SOLID TUMORS$3,299
M01 · FY2006 · RR · contact PI
CWRU/UHICC Phase I Trials of Anticancer Agents$620,535
U01 · FY2005 · CA
COMBRETASTATIN A-4 PHOSPHATE IN ADVANCED ANAPLASTIC THYROID CARCINOMA$91,542
M01 · FY2005 · RR
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$53,709
U01 · FY2005 · CA
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$45,288
U01 · FY2005 · CA
THALIDOMIDE AND DOCETAXEL FOR ADVANCED MALIGNANCIES$31,749
M01 · FY2005 · RR
17-DIMETHYLAMINOETHYLAMINO-17DEMETHOXYGELDANAMYCIN IN ADVANCED SOLID TUMORS$30,161
M01 · FY2005 · RR
PS-341 IN PATIENTS WITH ADVANCED MALIGNANCIES AND RENAL DYSFUNCTION$27,515
M01 · FY2005 · RR
SILICONE PHTHALOCYANINE 4 (PC4) PHOTODYNAMIC THERAPY FOR CUTANEOUS MALIGNANCIES$14,287
M01 · FY2005 · RR
EPOTHILONE B ANALOGUE BMS-247550 IN PTS WITH MALIGNANCIES AND LIVER DYSFUNCTION$12,171
M01 · FY2005 · RR
FENRETINIDE + PACLITAXEL + CISPLATIN FOR ADVANCED SOLID TUMORS$9,525
M01 · FY2005 · RR
STI571 IN ADV MALIGNANCIES AMP;VARYING DEGREES OF RENAL DYSFUNCTION$7,409
M01 · FY2005 · RR
COMBRETASTATIN/DOXORUBICIN/CISPLATIN FOR PATIENTS WITH THYROID CANCER$4,762
M01 · FY2005 · RR
BRYOSTATIN 1 + VINCRISTINE IN NON-HODGKIN'S LYMPHOMA POST TRANSPLANT$4,234
M01 · FY2005 · RR
CWRU/UHICC Phase I Trials of Anticancer Agents$724,297
U01 · FY2004 · CA
Combretastatin A-4 phosphate in advanced anaplastic carcinoma of the thyroid$67,571
M01 · FY2004 · RR
Thalidomide and docetaxel for advanced malignancies$47,373
M01 · FY2004 · RR
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$44,680
U01 · FY2004 · CA
STI571 in pts with advanced malignancies &varying degrees of renal dysfunction$19,831
M01 · FY2004 · RR
Oxaliplatin, irinotecan, and capecitabine in solid tumors$17,994
M01 · FY2004 · RR
STI571 in pts with advanced malignancies &varying levels of liver dysfunction$11,862
M01 · FY2004 · RR
Silicon phthalocyanine 4 (Pc4) + photodynamic therapy for cutaneous malignancies$11,017
M01 · FY2004 · RR
Bryostatin 1+vincristine in non-Hodgkin's lymphoma pts post transplantation$8,447
M01 · FY2004 · RR
PS-341 in patients with advanced malignancies and renal dysfunction$5,875
M01 · FY2004 · RR
SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck$367
M01 · FY2004 · RR
CWRU/UHICC Phase I Trials of Anticancer Agents$587,286
U01 · FY2003 · CA
Oral Chemotherapy in AIDS-related NHL in Uganda &Kenya$305,190
R01 · FY2003 · CA
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$239,239
U01 · FY2003 · CA
CWRU/UHICC PHASE I TRIALS OF ANTICANCER AGENTS$601,407
U01 · FY2002 · CA
Oral Chemotherapy in AIDS-related NHL in Uganda &Kenya$290,573
R01 · FY2002 · CA
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$109,869
U01 · FY2002 · CA
BRYOSTATIN 1 &VINCRISTINE IN B CELL MALIGNANCIES$0
M01 · FY2002 · RR
CA4P (INTRAVENOUS) IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2002 · RR
OXI 104 IN COMBINATION W/ CISPLATIN IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2002 · RR
REBECCAMYCIN ANALOG GIVEN 5 CONSECUTIVE DAYS IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2002 · RR
CWRU/UHICC PHASE I TRIALS OF ANTICANCER AGENTS$386,297
U01 · FY2001 · CA
Oral Chemotherapy in AIDS related NHL in Uganda &Kenya$326,919
R01 · FY2001 · CA
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$224,772
U01 · FY2001 · CA
CWRU/UHICC PHASE I TRIALS OF ANTICANCER AGENTS$160,417
U01 · FY2001 · CA
BRYOSTATIN 1 &VINCRISTINE IN B CELL MALIGNANCIES$0
M01 · FY2001 · RR
CA4P (INTRAVENOUS) IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2001 · RR
OXI 104 IN COMBINATION W/ CISPLATIN IN PATIENTS W/ ADVANCED CANCER$0
M01 · FY2001 · RR
REBECCAMYCIN ANALOG GIVEN 5 CONSECUTIVE DAYS IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2001 · RR
CWRU/UHICC PHASE I TRIALS OF ANTICANCER AGENTS$366,735
U01 · FY2000 · CA
CCM AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS UNIT$185,297
U01 · FY2000 · CA
CWRU/UHICC PHASE I TRIALS OF ANTICANCER AGENTS$33,850
U01 · FY2000 · CA
BRYOSTATIN 1 &VINCRISTINE IN B CELL MALIGNANCIES$19,199
M01 · FY2000 · RR
CA4P (INTRAVENOUS) IN PATIENTS W/ ADVANCED CANCER$19,199
M01 · FY2000 · RR
OXI 104 IN COMBINATION W/ CISPLATIN IN PATIENTS W/ ADVANCED CANCER$19,199
M01 · FY2000 · RR
REBECCAMYCIN ANALOG GIVEN 5 CONSECUTIVE DAYS IN PATIENTS WITH SOLID TUMORS$19,199
M01 · FY2000 · RR